MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
March 5, 2004
Paul Elliott
Martha, Martha, Martha She's guilty as charged. What can we all learn from Martha Stewart's misfortune. Don't buy or sell stocks on rumors. mark for My Articles similar articles
The Motley Fool
April 27, 2004
Alyce Lomax
Imagining ImClone It's been hard to ignore the lure of cancer drugs over the last several days. Today, ImClone shares leapt after the company reported stellar first-quarter profits, boosted by its launch of colon cancer drug Erbitux. mark for My Articles similar articles
The Motley Fool
September 1, 2004
Bill Mann
Triumph of Hope Over Reason A frighteningly expensive drug of marginal efficacy begets triple-digit multiples? Bring on the miracles. Standard & Poor's reiterated its "buy" rating of ImClone. mark for My Articles similar articles
BusinessWeek
March 8, 2004
Arnst & Ewing
The Odyssey Of A Cancer Drug How ImClone overcame scandal and FDA objections to get Erbitux to market mark for My Articles similar articles
The Motley Fool
July 20, 2006
Brian Lawler
No Surprises From ImClone ImClone's lead product experienced strong revenue growth in the second quarter. But biotech investing is fraught with risk. Investors, take note. mark for My Articles similar articles
The Motley Fool
January 29, 2007
Brian Lawler
ImClone Fights The Competition The drug developer's performance has been alright, but the competition is heating up. Investors, take note. mark for My Articles similar articles
The Motley Fool
April 20, 2004
Charly Travers
Great Googly Moogly, ImClone The biopharmaceutical company's stock is going crazy again. mark for My Articles similar articles
The Motley Fool
September 28, 2006
Brian Lawler
Amgen Secures Its Future FDA approval for the company's colorectal cancer drug is good news for its future prospects. Investors, take note. mark for My Articles similar articles
The Motley Fool
June 12, 2007
Brian Lawler
ImClone Tries To Improve Erbitux ImClone is running trials to see if the drug can be used in earlier stages of cancer. Investors shouldn't discount the importance of an approved drug's product label. mark for My Articles similar articles
The Motley Fool
September 11, 2008
Brian Lawler
ImClone and Bristol-Myers' Unfinished Business ImClone rejects Bristol's offer, but likely isn't done dealing with it yet. mark for My Articles similar articles
The Motley Fool
February 16, 2010
Brian Orelli
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. mark for My Articles similar articles
The Motley Fool
August 1, 2007
Brian Lawler
ImClone Inches Along ImClone reports slower than expected sales growth with its lead cancer fighting drug, Erbitux. ImClone needs to expand the use of Erbitux into new markets to return to a period of sustained top-line growth. mark for My Articles similar articles
The Motley Fool
March 24, 2004
Rick Aristotle Munarriz
Martha Washing Done? The worst may be behind Martha Stewart's media empire. Is the stock a buy? mark for My Articles similar articles
The Motley Fool
April 27, 2007
Brian Lawler
Tracking ImClone The biopharmaceutical releases first-quarter financial results. Investors, take note. mark for My Articles similar articles
The Motley Fool
April 28, 2008
Brian Lawler
ImClone on the Upswing The pharmaceutical's latest results show continuing improvement. mark for My Articles similar articles
The Motley Fool
April 5, 2007
Brian Lawler
ImClone Steps to the Front ImClone announces a successful clinical trial for the cancer drug Erbitux. Investors, take note. mark for My Articles similar articles
Fast Company
September 2004
Linda Tischler
The Trials of ImClone A founder in handcuffs, financials in disarray, and a vital product in doubt-for CEO Daniel Lynch, it was the turnaround from hell. mark for My Articles similar articles
The Motley Fool
October 18, 2004
Charly Travers
Biotech's 5-Baggers How can yesterday's biotech winners lead you to today's top performers? mark for My Articles similar articles
The Motley Fool
June 4, 2008
Brian Lawler
Erbitux's Deceptively Disappointing Results Poorly received lead-drug data batters ImClone shares. mark for My Articles similar articles
The Motley Fool
April 7, 2011
Brian Orelli
Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market. mark for My Articles similar articles
The Motley Fool
January 26, 2009
Brian Orelli
Which One of These Is Not Like the Other? Bristol-Myers and Eli Lilly run into some comparability issues. mark for My Articles similar articles
The Motley Fool
March 8, 2004
Dave Marino-Nachison
Martha Looks Around the Corner Stewart watchers are now guessing at the future of the home-making empire. mark for My Articles similar articles
The Motley Fool
September 13, 2007
Brian Lawler
ImClone Expanding on Erbitux ImClone's turnaround continues with positive results in a cancer study with their lead drug Erbitux. mark for My Articles similar articles
The Motley Fool
December 20, 2004
Charly Travers
More Trouble at Big Pharma AstraZeneca's lung cancer drug is not as effective as once hoped. mark for My Articles similar articles
The Motley Fool
August 1, 2008
Brian Lawler
Is $60 a Share Enough for ImClone? Bristol-Myers Squibb announced a $60-per-share offer for ImClone Systems, but are shareholders going to go for the deal? mark for My Articles similar articles
The Motley Fool
October 2, 2008
Brian Orelli
Will Lilly Buy ImClone's Troubles? Eli Lilly is reportedly ImClone's mystery suitor. Would it be a good deal? mark for My Articles similar articles
The Motley Fool
May 19, 2004
Rick Aristotle Munarriz
Martha Gets Canned Martha Stewart Living Omnimedia takes a break from its plans for world domination. mark for My Articles similar articles
The Motley Fool
May 3, 2004
Rich Smith
ImClone's Buy-and-Hold Lesson Long-term buy-and-hold investing could have saved Martha more than just jail time. mark for My Articles similar articles
The Motley Fool
November 19, 2004
Charly Travers
A New Drug for Lung Cancer Genentech and OSI's launch of Tarceva brings a new choice in the treatment of lung cancer. mark for My Articles similar articles
The Motley Fool
July 9, 2008
Brian Lawler
Predicting More Good News From Invitrogen Invitrogen gets a positive review from the FDA for one of its tests. mark for My Articles similar articles
The Motley Fool
June 18, 2010
Brian Orelli
Double the Approvals! Double the Fun! These twins will take it. sanofi-aventis and Novartis both received FDA approvals for their cancer drugs yesterday. mark for My Articles similar articles
The Motley Fool
February 26, 2011
Brian Orelli
FDA Applications and a Look Ahead It isn't pretty. mark for My Articles similar articles
The Motley Fool
October 30, 2007
Brian Lawler
ImClone Onward Global sales, and excitement about new label expansions for lead drug Erbitux, lift ImClone's third-quarter financial results. mark for My Articles similar articles
The Motley Fool
May 7, 2004
Alyce Lomax
A Martha Stewart Identity Crisis What's in a name? For Martha Stewart Living, it might be a matter of life-or-death. mark for My Articles similar articles
The Motley Fool
July 30, 2010
Brian Orelli
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. mark for My Articles similar articles
The Motley Fool
July 16, 2007
Brian Lawler
Slight Setback for ImClone ImClone announces a failed cancer study. Investors, take note. mark for My Articles similar articles
The Motley Fool
April 5, 2010
Brian Orelli
1 Month to Go! Is Dendreon a Buy? Only if you understand the risks. mark for My Articles similar articles
The Motley Fool
April 17, 2007
Brian Lawler
ImClone Loses an Indication ImClone's lead drug fails in a clinical trial. Investors, take note. mark for My Articles similar articles
The Motley Fool
January 30, 2004
David Murphy
Trying Times for Martha What does the Stewart trial mean for her company's bottom line? mark for My Articles similar articles
The Motley Fool
September 29, 2006
Brian Lawler
ImClone Under Siege Board member Carl Icahn moves to take control, and it appears as though shareholders agree. mark for My Articles similar articles
The Motley Fool
February 16, 2007
Brian Lawler
The Biotech Academy Awards Investors, here are some biotech Oscars for last year's performances: The Biotech Best Picture award -- Celgene... The Biotech Best Drama -- Elan and BiogenIdec... etc. mark for My Articles similar articles
The Motley Fool
July 16, 2004
Brian Gorman
Martha's Light Sentence Martha Stewart Living Omnimedia investors cheered her light sentence, but the fate of the queen of the domicile probably isn't that important. mark for My Articles similar articles
The Motley Fool
December 31, 2010
Brian Orelli
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. mark for My Articles similar articles
The Motley Fool
December 31, 2007
Brian Lawler
The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency. mark for My Articles similar articles
The Motley Fool
November 29, 2011
Brian Orelli
Winners and Losers of Roche's Avastin Woes What the FDA giveth, the FDA can taketh away. mark for My Articles similar articles
The Motley Fool
September 16, 2004
Seth Jayson
Martha Cleans Up There's no disguising the fact that this is about repairing a brand in order to sell more magazines, more towels at Kmart, and more books on Amazon.com. But that should be worth something to shareholders. mark for My Articles similar articles
Knowledge@Wharton Bristol-Myers Squibb Illustrates Woes of Ailing Pharmaceutical Industry The once-mighty pharmaceutical industry, for years the nation's most profitable, has begun to show some cracks. But no major U.S. drug maker seems to be facing more problems than Bristol-Myers Squibb. mark for My Articles similar articles
The Motley Fool
May 21, 2004
Bob Bobala
Martha Surges on Perjury A bump in the Martha Stewart case sends her company's stock to the moon. mark for My Articles similar articles
The Motley Fool
June 16, 2011
Brian Orelli
Are Two FDA Approvals in One Week a Positive Sign? Bristol-Myers Squibb received Food and Drug Administration approval for its kidney transplant drug Nulojix yesterday, marking the second approval this week from the FDA. mark for My Articles similar articles
Chemistry World
June 22, 2011
Sarah Houlton
US Approves Cancer Drugs Twice as Fast as Europe Cancer drugs are, on average, approved nearly twice as fast in the US than they are in Europe. mark for My Articles similar articles